How can we help you today?

Select the option that best describes your needs:

Medical Knowledge

I'm just reading and gaining Info

Exploring Treatment Options

I'm just finding out treatment options, cost, & hospital Info

Dr. Amol Akhade

Senior Consultant – Medical & Precision Oncology

Bone Marrow TransplantationHaematologyMedical OncologyPrecision Oncology

Affiliated hospitals:

About

Dr. Amol Akhade is a renowned medical and haemato-oncologist with over 18 years of experience in treating cancer, focusing on personalised approaches and innovative therapies. Trained at the Tata Memorial Hospital, he is highly skilled in treating solid tumours and haematologic malignancies and is an expert in both autologous and allogeneic bone marrow transplants.

Years of Experience

18

Languages

English, Hindi, Marathi

Qualifications

  • ✓ MBBS – KEM Hospital, Mumbai
  • ✓ MD (Internal Medicine) – KEM Hospital, Mumbai
  • ✓ DM (Medical Oncology) – Tata Memorial Hospital, Mumbai

Expertise & Skills

  • ✓ 18+ years of experience in medical and haemato-oncology
  • ✓ Trained at Tata Memorial Hospital, Mumbai – premier cancer institute in India
  • ✓ Expert in solid tumours and haematologic malignancies including lymphoma, leukaemia, and myeloma
  • ✓ Expert in autologous and allogeneic bone marrow transplants
  • ✓ Actively engaged in multidisciplinary tumour boards
  • ✓ Special interests: clinical trials and real-world data in oncology, Precision Oncology, Chemotherapy, Immunotherapy, Targeted Therapy, Head and Neck Cancers, Lung Cancer, Breast Cancer, GI and Gynaecological Cancers

Achievements

  • ✓ DNB faculty and recognised speaker in oncology
  • ✓ Member: American Society of Clinical Oncology (ASCO), European Society for Medical Oncology (ESMO)
  • ✓ Published in Lancet Oncology, JCO Global Oncology, BMJ Oncology, Indian Journal of Cancer, Indian Journal of Medical and Paediatric Oncology, South Asian Journal of Cancer, ecancermedicalscience
  • ✓ Retrospective audit of clinicopathological attributes and treatment outcomes of adolescent and young adult non-Hodgkin lymphomas (Indian Journal of Medical and Paediatric Oncology)
  • ✓ Global Consequences of the US FDA's accelerated approval of cancer drugs (Lancet Oncology)
  • ✓ Geriatric oncology in LMICs: It is time to mature (BMJ Oncology)
  • ✓ Contributing to consensus guidelines for CDK 4/6 inhibitors in early breast cancer management